Braveheart Bio/$BRVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Braveheart Bio
Braveheart Bio is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its sole disclosed product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for both obstructive and non-obstructive forms of HCM. The company obtained exclusive rights outside Greater China to BHB-1893 from Jiangsu Hengrui Pharmaceuticals in September 2025; prior clinical studies of the asset were sponsored by Hengrui, principally in China. Braveheart Bio is headquartered in San Francisco, California, and was founded in 2024. Its development strategy centers on advancing BHB-1893 through global late-stage trials, while Hengrui retains development and commercialization activities in Greater China.
Ticker
$BRVE
Sector
Primary listing
Employees
-
Headquarters
Website
Braveheart Bio Metrics
BasicAdvanced
$1.8bn
-
-$2.63
-
-
Price and volume
Market cap
$1.8bn
52-week high
$31.56
52-week low
$29.42
Financial strength
Current ratio
8.106
Quick ratio
8.056
Long term debt to equity
0.411
Total debt to equity
0.933
Profitability
Management effectiveness
Valuation
Price to book
-11.59
Price to tangible book (TTM)
-11.59
Price to free cash flow (TTM)
-20.878
Free cash flow yield (TTM)
-4.79%
Free cash flow per share (TTM)
-1.437
Growth
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.